NEW YORK – Myriad Genetics on Monday announced plans to expand access to its myChoice CDx in Europe and China.
In China, Myriad signed a development and commercial agreement with Burning Rock Biotech to use its myChoice homologous recombination deficiency (HRD) test in Phase III drug development studies and in clinics.
The myChoice test identifies cancer patients whose tumors cannot repair DNA damage and are therefore more sensitive to platinum drugs or PARP inhibitors. In the US, the test is approved to identify advanced ovarian cancer patients with HRD-positive tumors, who may respond well to the PARP inhibitor olaparib (AstraZeneca/Merck's Lynparza) plus bevacizumab (Genentech's Avastin) as a maintenance treatment after first-line, platinum-based chemotherapy.
The European Commission earlier this month approved the olaparib-bevacizumab combination for the same indication. To support patients' access to this treatment in Europe, Myriad said it will license its technology and provide technical support to pathology institutes in Germany and France. European labs will perform the CE-marked myChoice CDx PLUS test, while Myriad will also support European customers by conducting testing out of its Salt Lake City, Utah-based lab.
"Through close collaboration with innovative laboratories in Europe and with Burning Rock in China, we are bringing the clinical benefits of myChoice testing to additional markets and patients, advancing personalized treatment for patients around the world," Nicole Lambert, president of Myriad Genetic Laboratories, said in a statement.